Results 241 to 250 of about 22,816,528 (289)
Some of the next articles are maybe not open access.
Protein C Concentrates for Therapeutic Use.
Lancet, The, 1983S Viganò, P M Mannucci
exaly +3 more sources
Protein C Concentrates for Therapeutic Use
Lancet, The, 1982A W Broekmans, R M Bertina
exaly +3 more sources
Protein C in Clinical Factor IX Concentrates.
Lancet, The, 1983M J Seghatchian, M J Seghatchian
exaly +3 more sources
Use of protein C concentrate in neonatal period.
Levels of protein C, low at birth, physiologically Increase until six months of age and achieve the adult range after puberty. Protein C deficiency may be congenital or acquired. Severe protein C deficiency is a rare autosomal recessive disorder that usually presents in neonatal period with purpura fulminans. Acquired protein C deficiency may be caused
De Carolis, Maria Pia
openaire +3 more sources
Homozygous protein C deficiency—management with protein C concentrate
European Journal of Pediatrics, 1995Two unrelated female infants with homozygous protein C (Pr C) deficiency are reported. Both are of U.K. Pakistani origin and in each case the parents are consanguinous. A previous sibling had died in each family. Both sets of parents were shown to be carriers. The concentration of Pr C in both infants was low at birth.
V, Baliga +5 more
openaire +2 more sources
SUBCUTANEOUS ADMINISTRATION OF PROTEIN C CONCENTRATE
Pediatric Hematology and Oncology, 2004Children born with severe homozygous protein C deficiency do not survive beyond the neonatal period unless they receive protein C replacement. Protein C concentrate (Baxter Biosciences, Vienna) is usually given intravenously via a central venous catheter The authors describe 2 children in whom protein C concentrate was successfully administered by ...
M, Mathias +3 more
openaire +2 more sources
DEVELOPMENT OF A PROTEIN C CONCENTRATE
Thrombosis and Haemostasis, 1987A Protein C (PC) concentrate may be useful in treating patients with congenital or acquired Protein C deficiencies. A method for preparation of a human Protein C concentrate has been developed using a by-product of American Red Cross Factor IX production as the starting material (Menache et. al. Blood, 64, 1220).
Prabir Bhattacharya +2 more
openaire +1 more source
Treatment of homozygous protein C deficiency with subcutaneous protein C concentrate
British Journal of Haematology, 1996Subcutaneous protein C concentrate (Immuno, Vienna) was used to treat a child with homozygous protein C deficiency who was formerly treated with intravenous protein C concentrate. After 3000 units subcutaneous protein C concentrate (250 iu/kg), protective protein C levels were maintained for 48h after infusion, with peak levels at 12h.
A M, Minford +3 more
openaire +2 more sources

